10-K: IR-Med, Inc. Reports 2023 Financial Results and Provides Business Update

IR-Med, Inc. released its 2023 annual report, detailing financial results and operational updates, including a focus on its PressureSafe device and ongoing financial challenges.

Summary

• IR-Med, Inc. reported a net loss of approximately $4.9 million for 2023, compared to a net loss of $4.7 million in 2022.
• The company's operating expenses included $2.1 million in research and development, $822,000 in marketing, and $2 million in general and administrative costs.
• As of April 1, 2024, the company had 69,931,056 shares of common stock outstanding.
• The company had $767,000 in cash resources and $634,000 of liabilities as of December 31, 2023.
• The company's operations are currently limited to critical actions due to financial difficulties.
• The development and commercialization plans for the PressureSafe, DiaSafe, and Nobiotics devices are on hold pending additional funding.
• The company is developing a technology platform based on infrared spectroscopy and AI analysis for point-of-care decision support devices.
• The PressureSafe device is planned to be launched in 2024, following FDA registration and listing.
• The Israeli Innovation Authority approved a program to develop a diabetic foot ulcer device with a budget of approximately $1 million, including a 50% grant.
• The company is also in the preliminary stage of research and development of an innovative otoscope, Nobiotics.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges and operational delays, overshadowing the potential of the company's technology. The going concern warning and the termination of most employees are major negative indicators.

Positives

• The PressureSafe device has shown promising results in usability studies, demonstrating high efficacy in detecting pressure injuries.
• The company has secured a grant from the Israeli Innovation Authority for the development of a diabetic foot ulcer device.
• The company has an exclusive distribution agreement in place for the US market.
• The company has a strong research and development team and a patent portfolio protecting its core technologies.
• The company is targeting large and growing patient populations with significant unmet medical needs.

Negatives

• The company has a history of significant operating losses and expects to continue incurring losses for the foreseeable future.
• The company's operations are currently limited to critical actions due to financial difficulties.
• The development and commercialization plans for the PressureSafe, DiaSafe, and Nobiotics devices are on hold pending additional funding.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company has limited operating history and may face challenges in achieving its business goals.
• The company's quarterly results may fluctuate significantly, and period-to-period comparisons may not be meaningful.
• The company's technology development is headquartered in Israel, which may be affected by political and military instability.
• The company has terminated the employment of most of its employees, including its CEO, due to financial difficulties.

Risks

• The company will need substantial additional funding to continue operations, which could result in significant dilution or restrictions on business activities.
• The company may not be able to raise capital when needed, which would force it to delay, reduce, or eliminate product development programs.
• Medical device development is a lengthy and expensive process with an uncertain outcome.
• The company currently has no products approved for commercial sale and may not be able to successfully develop and commercialize its products.
• The size and future growth of the market for the company's planned devices may be smaller than estimated.
• The company may be subject to numerous and varying privacy and security laws, and failure to comply could result in penalties and reputational damage.
• The company may be sued by third parties for alleged infringement of their proprietary rights.
• The company's results may be adversely affected by economic restrictions imposed on, and political and military instability in Israel, including the Israel-Hamas war.
• The company's common stock is subject to the penny stock rules of the SEC and the trading market in the securities is limited.
• The company may have become exposed to material liabilities that were not discovered before, and have not been discovered since, due to the closing of the Acquisition.

Future Outlook

The company plans to launch the PressureSafe device in 2024, pending FDA approval, and is working on the development of DiaSafe and Nobiotics. The company's future success depends on its ability to secure additional funding and achieve commercial success with its products.

Management Comments

• The company's operations will be limited to critical actions in order to save funds.
• The description of our three product candidates development and commercialization plans are currently on hold and are subject to us being able to raise additional funds to support our operations and to further develop and commercialize our products.

Industry Context

The company operates in the competitive medical device market, facing competition from established companies and new technologies. The company's focus on non-invasive diagnostics and AI-driven solutions aligns with current trends in healthcare technology.

Comparison to Industry Standards

• The company's PressureSafe device competes with Bruins Biometrics Provizio SEM Scanner, which uses electro-resistance measurement, while PressureSafe uses optical monitoring and AI.
• The company's technology is based on light reflection from the skin, which is different from other methods such as skin conductivity.
• The company's focus on early detection of pressure injuries and diabetic foot ulcers addresses a significant unmet need in the healthcare industry.
• The company's development of Nobiotics to differentiate between viral and bacterial ear infections aligns with the global goal of reducing antibiotic consumption.

Management Changes

Legal Proceedings

• A lawsuit was filed against the Company, the Subsidiary and Mr. Aharon Klein, alleging breach of contract based on non-payment of amounts purportedly owed to the Plaintiff in respect of the services rendered, including the market value of the Companys common stock that the Plaintiff alleges should have been issued to him in respect of his services.

Related Party Transactions

• The company has loans from certain stockholders with interest rates ranging from 2.42% to 2.90%.
• The company has a convertible bridge loan with certain shareholders with an interest rate of 3% compounded annually.
• The company paid an aggregate consideration of US$161 thousand and US$220 thousand, respectively, in respect of research and development services to two directors and to an entity controlled by a shareholder of the Company.
• The company paid an aggregate consideration of $150 thousand and $111 thousand, respectively, in respect consulting services to one shareholder of the Company and his relative.
• The company paid an aggregate consideration of $36 thousand and $130 thousand respectively in respect of their services to four of the Company non-employee directors.
• The company paid a yearly amount of $80 thousand and $51 thousand to an entity controlled by two of the Companys directors for rent and office services, respectively.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial challenges and potential dilution from future capital raises.
• Employees have been impacted by the termination of most of the workforce due to financial difficulties.
• Customers may experience delays in the availability of the company's products due to the hold on development and commercialization plans.
• Suppliers may face uncertainty regarding future orders and payments due to the company's financial situation.
• Creditors may face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to complete the development of the commercial version of the PressureSafe device.
• The company plans to launch the PressureSafe device in 2024, following FDA registration and listing.
• The company plans to commence a clinical trial in the center of Israel's leading diabetes clinic for the diabetic foot ulcer device.
• The company aims to conduct an American based trial for the diabetic foot ulcer device, potentially during the first half of 2025.
• The company plans to seek out collaborative arrangements with major healthcare providers to facilitate market adoption of its product candidates.
• The company plans to engage with private insurance plans to develop reimbursement programs encouraging the use of its product candidates.

Key Dates

Keywords

PressureSafe, Diabetic Foot Ulcers, Nobiotics, Infrared Spectroscopy, Artificial Intelligence, Medical Devices, Pressure Injuries, Otitis Media, Diagnostics, Healthcare, FDA, Clinical Trials, Israel Innovation Authority, Financial Results, Going Concern